Combination of triciribine and p38 MAPK inhibitor PD169316 enhances the differentiation effect on myeloid leukemia cells

• Yuri Sato-Nagaoka ,

  Contributed equally to this work with: Yuri Sato-Nagaoka, Susumu Suzuki

  Roles Investigation

  Affiliation Department of Clinical Laboratory, Tohoku Medical and Pharmaceutical University Hospital, Sendai, Japan

  ⨯
• Susumu Suzuki ,

  Contributed equally to this work with: Yuri Sato-Nagaoka, Susumu Suzuki

  Roles Data curation, Formal analysis, Investigation

  Affiliations Department of Clinical Laboratory, Tohoku Medical and Pharmaceutical University Hospital, Sendai, Japan, Division of Laboratory Medicine, Faculty of Medicine, Tohoku Medical and Pharmaceutical University, Sendai, Japan, Institute of Molecular Biomembrane and Glycobiology, Tohoku Medical and Pharmaceutical University, Sendai, Miyagi, Japan

  ⨯
• Souma Suzuki,

  Roles Investigation

  Affiliation Division of Laboratory Medicine, Faculty of Medicine, Tohoku Medical and Pharmaceutical University, Sendai, Japan

  ⨯
• Shinichiro Takahashi

  Roles Conceptualization, Data curation, Formal analysis, Funding acquisition, Project administration, Resources, Writing – original draft, Writing – review & editing

  * E-mail: shintakahashi@tohoku-mpu.ac.jp

  Affiliations Department of Clinical Laboratory, Tohoku Medical and Pharmaceutical University Hospital, Sendai, Japan, Division of Laboratory Medicine, Faculty of Medicine, Tohoku Medical and Pharmaceutical University, Sendai, Japan, Institute of Molecular Biomembrane and Glycobiology, Tohoku Medical and Pharmaceutical University, Sendai, Miyagi, Japan

  https://orcid.org/0000-0003-0011-6065

  ⨯